Clinical Trials

55 results for Prostate Cancer


A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: ProstAtak®(AdV-tk) + valacyclovir, Biological: Placebo + valacyclovir
  • Study ID: NCT01436968
View Trial

A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

  • Condition: Adenocarcinoma of Prostate, Progression of Prostate Cancer
  • Intervention: Drug: Cabazitaxel, Radiation: Pelvic radiotherapy, Radiation: prostate radiotherapy
  • Study ID: NCT01952223
View Trial

Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
  • Study ID: NCT01985828
View Trial

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

  • Condition: Prostate Cancer
  • Study ID: NCT01961713
View Trial

Evaluation of the TULSA-PRO MRI-guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Device: MRI-guided Transurethral Ultrasound Ablation
  • Study ID: NCT02766543
View Trial

A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pyruvate (13C)
  • Study ID: NCT02526368
View Trial

The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

  • Condition: Prostate Cancer
  • Intervention: Other: Active surveillance
  • Study ID: NCT00949819
View Trial

Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost

  • Condition: Prostate Cancer
  • Intervention: Radiation: Stereotactic Ablative Body Radiotherapy as Monotherapy, Radiation: Stereotactic Ablative Body Radiotherapy as a Boost
  • Study ID: NCT02016248
View Trial

Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.

  • Condition: Adenocarcinoma of the Prostate
  • Intervention: Radiation: Stereotactic Radiosurgical Boost3, Drug: Casodex, Drug: Leuprolide
  • Study ID: NCT02064036
View Trial

Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial

  • Condition: Prostatic Neoplasms
  • Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
  • Study ID: NCT02102477
View Trial

Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
  • Study ID: NCT02643511
View Trial

Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: CyberKnife Boost
  • Study ID: NCT01508390
View Trial

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study

  • Condition: Locally Advanced and Metastatic Prostate Cancer
  • Intervention: Procedure: Radical prostatectomy
  • Study ID: NCT02971358
View Trial

Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate

  • Condition: Prostate Cancer
  • Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
  • Study ID: NCT01492972
View Trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study

  • Condition: Prostate Cancer
  • Intervention: Drug: Metformin, Drug: Placebo
  • Study ID: NCT01864096
View Trial

Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy

  • Condition: Circulating Tumor Cells
  • Intervention: Other: Blood draw
  • Study ID: NCT02449837
View Trial

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

  • Condition: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
  • Intervention: Genetic: PCR/PCR/LDR Strategy
  • Study ID: NCT00579514
View Trial

Collection of Blood From Patients With Prostate Cancer

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00923221
View Trial

Canary Prostate Active Surveillance Study

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00756665
View Trial

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
  • Study ID: NCT00588185
View Trial

A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch

  • Condition: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
  • Intervention: Radiation: Brachytherapy
  • Study ID: NCT00924027
View Trial

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

  • Condition: Prostate Cancer
  • Intervention: Drug: Ra223, Drug: Enzalutamide
  • Study ID: NCT02194842
View Trial

Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer

  • Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
  • Study ID: NCT00050752
View Trial

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

  • Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
  • Study ID: NCT00026884
View Trial

MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness

  • Condition: Prostatic Neoplasms, Genital Neoplasms, Male, Prostatic Diseases
  • Study ID: NCT01464216
View Trial

A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

  • Condition: Prostate Cancer, Prostate Adenocarcinoma
  • Intervention: Radiation: Standard Salvage Radiation Treatment (SSRT), Radiation: Mapped Tumor Salvage RT (MTSRT), Behavioral: Expanded Prostate Cancer Index Composite-SF12, Behavioral: Memory Anxiety Scale for Prostate Cancer patients, Behavioral: International Prostate Symptom Score (IPSS)
  • Study ID: NCT01411345
View Trial

A Phase II Randomized Control Trial of Conventional Versus Hypofractionated Radiation Regimen in Single Phase Using IMRT Technique and Long Term Androgen Suppression Therapy in High-risk Prostate Cancer Patients.

  • Condition: High-risk Prostate Cancer
  • Intervention: Radiation: Standard Radiation Treatment, Radiation: Hypofractionated radiation treatment
  • Study ID: NCT01488968
View Trial

Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
  • Study ID: NCT00969111
View Trial

A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

  • Condition: Prostate Cancer
  • Intervention: Drug: 177Lu-J591, Drug: Ketoconazole, Drug: Hydrocortisone, Drug: 111In-J591
  • Study ID: NCT00859781
View Trial

A Randomized Trial of Modifications to Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
  • Study ID: NCT01407263
View Trial

Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition

  • Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
  • Study ID: NCT01441089
View Trial

Biospecimen Acquisition From Human Subjects

  • Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
  • Study ID: NCT00034216
View Trial

Phase I/II Study of PROSTVAC in Combination With Nivolumab and / or Ipilimumab in Men With Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: PROSTVAC-V/F, Drug: Nivolumab, Drug: Ipilimumab
  • Study ID: NCT02933255
View Trial

HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields

  • Condition: Prostate Cancer
  • Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
  • Study ID: NCT02918253
View Trial

Active Surveillance With or Without a 6 Months Apalutamide Treatment in Low Risk Prostate Cancer: A Phase II Randomized Multicenter Trial

  • Condition: Low Risk Prostate Cancer
  • Intervention: Drug: Apalutamide
  • Study ID: NCT03088124
View Trial

Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)

  • Condition: Post Prostatectomy
  • Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03160794
View Trial

A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: Nivolumab, Biological: Ipilimumab
  • Study ID: NCT02985957
View Trial

Robotic and Focused Stereotactic Radiation Treatment of Good Prognosis Prostatic Adenocarcinoma

  • Condition: Prostate Cancer
  • Intervention: Radiation: Cyberknife
  • Study ID: NCT03284151
View Trial

Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of t

  • Condition: Prostate Cancer
  • Intervention: Drug: Degarelix, Drug: approved GnRH agonist, Radiation: Radiotherapy
  • Study ID: NCT02799706
View Trial

Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer

  • Condition: Health Status Unknown, PSA Progression
  • Intervention: Procedure: Biopsy of Prostate, Other: Laboratory Biomarker Analysis, Diagnostic Test: Magnetic Resonance Imaging, Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
  • Study ID: NCT03234556
View Trial

Pilot Study of Focal Salvage HDR Prostate Brachytherapy

  • Condition: Prostate Cancer
  • Intervention: Radiation: focal salvage HDR prostate brachytherapy
  • Study ID: NCT01583920
View Trial

A Phase II Randomized, Open-Label, Two-Arm Study of a Low-Fat Diet With Fish Oil Capsules vs. a Control Group in Men on Active Surveillance for Prostate Cancer

  • Condition: Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
  • Intervention: Behavioral: behavioral dietary intervention, Behavioral: behavioral dietary intervention, Dietary Supplement: omega-3 fatty acid, Other: laboratory biomarker analysis
  • Study ID: NCT02176902
View Trial

Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial

  • Condition: Prostate Cancer
  • Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
  • Study ID: NCT03482089
View Trial

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

  • Condition: Prostate Cancer, Localized Malignant Neoplasm
  • Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT01766492
View Trial

A Randomized Clinical Trial of Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer

  • Condition: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
  • Intervention: Behavioral: Exercise
  • Study ID: NCT02435472
View Trial

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

  • Condition: Stage II Prostate Adenocarcinoma
  • Intervention: Radiation: Intensity-Modulated Radiation Therapy (IMRT), Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT03367702
View Trial

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

  • Condition: Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Pro
  • Intervention: Drug: Carboplatin, Drug: Cisplatin, Drug: Docetaxel, Drug: Etoposide, Biological: Pembrolizumab
  • Study ID: NCT03582475
View Trial

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
  • Study ID: NCT03753243
View Trial

A Phase 1/2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Ibrutinib
  • Study ID: NCT02643667
View Trial

Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
  • Study ID: NCT03568188
View Trial